Flagship Biosciences, Westminster, Colo, has launched TissueInsight, a new clinical diagnostics immunooncology service. TissueInsight provides Clinical Laboratory Improvement Amendments (CLIA)-reportable PD-L1 results along with data about the tumor microenvironment (TME). “Flagship’s TissueInsight is a service that aids pathologists, oncologists, and immunologists in optimizing care for cancer patients,” says Trevor Johnson, Flagship CEO. “It provides immediate image analysis results without the need for an upfront monetary investment, internal development time or validation. TissueInsight reports can also be customized using additional biomarkers and image analysis.” Flagship’s exclusive, targeted testing in its College of American Pathologists (CAP)-accredited and CLIA-certified lab delivers the highly accurate tissue scoring needed for precision medicine. TissueInsight gives rapid, data-rich tissue interpretations and removes the inherent variability of subjective manual tissue scoring. Along with its CLIA-reportable results, TissueInsight TME data includes information on tumor infiltrating lymphocytes (TILs) and macrophages. “I’m extremely pleased to bring this new clinical diagnostics service to the market,” said Johnson. “Flagship’s scientific process, machine learning, and laboratory capabilities are enabling us to work with clinicians to expand immunooncology diagnostic tissue tests that will make their work more efficient and better help them to deliver on the promise of precision medicine for their patients.” For more information, visit Flagship Biosciences.